BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric StudyZacks Investment Research • 04/03/25
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with PhenylketonuriaPRNewsWire • 04/02/25
5 Historically Cheap Growth Stocks to Buy With Confidence in the Wake of the Nasdaq CorrectionThe Motley Fool • 03/27/25
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/21/25
BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics MeetingPRNewsWire • 03/20/25
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"Zacks Investment Research • 03/12/25
Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to TradeZacks Investment Research • 03/12/25
4 Discounted PEG Stocks Offering the Best Returns to Value InvestorsZacks Investment Research • 03/10/25
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MAPRNewsWire • 02/25/25
Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect?Zacks Investment Research • 02/24/25
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 ViewZacks Investment Research • 02/20/25
BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/19/25
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 GuidancePRNewsWire • 02/19/25